IL325134A - Antibodies directed against pvrig and their uses - Google Patents

Antibodies directed against pvrig and their uses

Info

Publication number
IL325134A
IL325134A IL325134A IL32513425A IL325134A IL 325134 A IL325134 A IL 325134A IL 325134 A IL325134 A IL 325134A IL 32513425 A IL32513425 A IL 32513425A IL 325134 A IL325134 A IL 325134A
Authority
IL
Israel
Prior art keywords
antibody
cancer
antigen
seq
binding portion
Prior art date
Application number
IL325134A
Other languages
English (en)
Hebrew (he)
Inventor
Baotian Yang
Yong Zheng
Cong Kong
Zhili Yao
Siwei Nie
Jijie Gu
Original Assignee
Wuxi Biologics Ireland Ltd
Baotian Yang
Yong Zheng
Cong Kong
Zhili Yao
Siwei Nie
Jijie Gu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuxi Biologics Ireland Ltd, Baotian Yang, Yong Zheng, Cong Kong, Zhili Yao, Siwei Nie, Jijie Gu filed Critical Wuxi Biologics Ireland Ltd
Publication of IL325134A publication Critical patent/IL325134A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL325134A 2023-06-06 2024-06-05 Antibodies directed against pvrig and their uses IL325134A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023098601 2023-06-06
PCT/CN2024/097578 WO2024251160A1 (fr) 2023-06-06 2024-06-05 Anticorps anti-pvrig et leurs utilisations

Publications (1)

Publication Number Publication Date
IL325134A true IL325134A (en) 2026-02-01

Family

ID=93795065

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325134A IL325134A (en) 2023-06-06 2024-06-05 Antibodies directed against pvrig and their uses

Country Status (8)

Country Link
EP (1) EP4724494A1 (fr)
KR (1) KR20260036406A (fr)
CN (1) CN121646607A (fr)
AU (1) AU2024283832A1 (fr)
IL (1) IL325134A (fr)
MX (1) MX2025014704A (fr)
TW (1) TW202502812A (fr)
WO (1) WO2024251160A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3653221T5 (da) * 2015-02-19 2024-08-26 Compugen Ltd Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
EP4003417A2 (fr) * 2019-07-29 2022-06-01 Compugen Ltd. Formulations d'anticorps anti-pvrig et leurs utilisations
CA3170025A1 (fr) * 2020-03-13 2021-09-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Proteine de liaison a pvgrig et ses utilisations medicales
US20240343803A1 (en) * 2021-07-30 2024-10-17 Shandong Simcere Biopharmaceutical Co., Ltd. Anti-Pvrig/Anti-Tigit Bispecific Antibodies And Applications Thereof
CN114644711B (zh) * 2022-03-07 2025-03-04 南京诺艾新生物技术有限公司 重组抗人pvrig抗体及应用

Also Published As

Publication number Publication date
CN121646607A (zh) 2026-03-10
WO2024251160A1 (fr) 2024-12-12
KR20260036406A (ko) 2026-03-16
MX2025014704A (es) 2026-03-02
TW202502812A (zh) 2025-01-16
EP4724494A1 (fr) 2026-04-15
AU2024283832A1 (en) 2026-01-29

Similar Documents

Publication Publication Date Title
WO2019214624A1 (fr) Anticorps entièrement humains dirigés contre ox40, procédé de préparation correspondant, et utilisation associée
US12410250B2 (en) Anti-CD47 antibodies and uses thereof
US20230242645A1 (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
US12054554B2 (en) Monoclonal antibody against human 4-1BB, method for preparing the same, and use thereof
WO2021057930A1 (fr) Nouvel anticorps bispécifique anti-pd-l1/anti-lag-3 et ses utilisations
US20210340252A1 (en) Anti-tim-3 antibodies and uses thereof
US20230348609A1 (en) Cd40 agonistic antibody and method of use
WO2024251160A1 (fr) Anticorps anti-pvrig et leurs utilisations
WO2024251140A1 (fr) Anticorps anti-tigit et leurs utilisations
WO2024251161A1 (fr) Anticorps anti-tigit x pvrig et leurs utilisations
WO2026037400A1 (fr) Anticorps anti-msln et leurs utilisations
US20240034786A1 (en) An antibody against p-cadherin and uses thereof
WO2020119789A1 (fr) Anticorps entièrement humains dirigés contre ox40, procédé de préparation correspondant, et utilisation associée
WO2020119792A1 (fr) Anticorps humanisés dirigés contre ox40, procédé de préparation de ceux-ci et utilisation associée
WO2020119793A1 (fr) Anticorps humanisés dirigés contre ox40, procédé de préparation correspondant, et utilisation associée
WO2025104253A1 (fr) Anticorps anti-muc16 et utilisations
AU2024380169A1 (en) Anti-muc16 antibodies and uses thereof
HK40082317A (en) Fully human antibodies against ox40, method for preparing the same, and use thereof